Evidence-based initiation of dopaminergic therapy in Parkinson's disease

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Miyasaki, Janis M ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Dopamine agonists; Evidence based practice; Initiation of therapy; Levodopa; Parkinson disease

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADL DISABILITY; ANTIOXIDANT ACTIVITY; BASAL GANGLION; BINGE EATING DISORDER; CONFERENCE PAPER; DRUG DOSE TITRATION; DRUG POTENCY; DYSKINESIA; EDEMA; EPWORTH SLEEPINESS SCALE; EVIDENCE BASED MEDICINE; HALLUCINATION; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LEG EDEMA; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOLOGICAL SHOPPING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SOMNOLENCE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; REVIEW; STANDARD;

DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE;

EID: 80053346792     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5718-x     Document Type: Conference Paper

References (33)

1. Adams RN, Murrill E, McCreery R, Blank L, Karolczak M (1972) 6-Hydroxydopamine a new oxidation mechanism. Eur J Pharmacol 17:287-292
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental 'disorders, fourth edition (DSM-IV-TR). American Psychiatric Publishing, Washington, DC
3. Clement MV, Long LH, Ramalingam J, Halliwell B (2002) The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 81:414-421
4. de Bie R, Miyasaki J, Lang AE, Fox SH (2007) Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease. Can J Neurol Sci 34:438-442 (Pubitemid 350248272)
5. Du F, Qian ZM, Zhu L, Wu XM, Yung WH, Tsim TY, Ke Y (2009) L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PloS ONE (Electronic Resource) 4(2):e4593
6. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. NEJM 351(24):2498-2508
7. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonis treatment and age at motor symptoms onset. J Psychopharmacol 21(5):501-506 (Pubitemid 47106924)
8. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson's disease: is it the drugs or the disease? Neuorlogy 67(5):853-858 (Pubitemid 44394202)
9. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 14:633-643
10. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian movement disorders group. JAMA 287:255-263
11. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson's disease research group of the United Kingdom (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71:474-480
12. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS (2009) Nonmotor symptoms in de novo Parkinson's disease before and after dopaminergic treatment. J Neurol Sci 15(287):200-204
13. Kostic V, Przedborski S, Flaster MS, Stemic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41:202-205
14. Marin C, Aguilar E, Mengod G, Cortes R, Obeso JA (2009) Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats. Eur J Neurosci 30:823-832
15. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G (2004) Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22-28 (Pubitemid 38559616)
16. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes J (1997) Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 104:317-328 (Pubitemid 27379892)
17. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson's disease - an evidence-based review. Neurology 58:11-17
18. Montel S, Bonnet AM, Bungener C (2009) Quality of life inr elation to mood, coping strategies and dyskinesia in Parkinson's disease. J Geriatr Psychiatry Neurol 22:95-102
19. Nair VD, Olanow CW, Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25-32 (Pubitemid 36819497)
20. Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson's disease. Ann N Y Acad Sci 786:217-233
21. Parkinson study group CALM cohort investigators (2009) Longterm effect of initiating pramipexole vs levodopa in early Parkinson's disease. Arch Neurol 66:563-570
22. Parkinson study group (2002) Pramipexole versus levodopa as initial treatment for Parkinson's disease. JAMA 284:1931-1938
23. Parkinson study group (2000) Beta CIT-SPECT assessment of progression of Parkinson's disease in subjects participating in the CALM-PD study. Neurology 54:A90
24. Parkinson study group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287:1653-1661
25. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness and dopamine agonists in Parkinson's disease. Mov Disord 18:659-667 (Pubitemid 36790281)
26. Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P, The Chinese Parkinson study group (2009) Health related quality of life in early Parkinson's disease: impact of motor and nonmotor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767-771
27. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A 5-year study of dyskinesias in patients with early Parkinson's disease who were treated with ropinirole or levodopa. NEJM 342:1484-1491 (Pubitemid 30318272)
28. Suzuki K, Miyamoto T, Miyamoto M, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H, Iwasaki YM, Iijima M, Hirata K (2008) Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. J Neurol Sci 271:47-52
29. Tanaka M, Sotomatsu A, Kanai H, Hirai S (1991) Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 101:198-203
30. van Rooden SM, Visser M, Verbaan, Marinus J, van Hilten JJ (2009) Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry 80:846-850
31. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in parkinson disease. Neurology 67:1254-1257 (Pubitemid 44563838)
32. Webster DD (1969) Quantitative measurements of L-dopa therapy in Parkinson's disease. Trans Am Neurol Assoc 94:348-350
33. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J, Wunderlich GR, Lang AE (2008) Mov Disord 23(S1)Poster